# Regeneron and Alnylam Win FDA Approval for Livsayis in Adults

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/61315
Published: 2026-11-19T12:23:40.000Z
Updated: 2026-11-19T12:23:40.000Z
Section: Business

> The RNA therapeutic, identified as Livsayis (cemdisiran), was approved to treat adults with myasthenia gravis, a chronic autoimmune condition.

The Food and Drug Administration approved Livsayis (cemdisiran), a small interfering RNA therapeutic developed by Regeneron Pharmaceuticals with Alnylam Pharmaceuticals, for adults with myasthenia gravis, a chronic autoimmune condition.


